INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
基本信息
- 批准号:3175180
- 负责人:
- 金额:$ 14.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1984
- 资助国家:美国
- 起止时间:1984-12-01 至 1997-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The enzyme lysyl oxidase functions as a suppressor of the
phenotypic expression of the ras oncogene. NIH 3T3 mouse cells
transformed by LTR-c-H-ras expressed very low levels of lysyl
oxidase; expression was restored after interferon beta-mediated
reversion. Revertants were retransformed by a lysyl oxidase
antisense expression construct; the original transformed cells were
reverted after transfection with a lysyl oxidase sense expression
construct. Lysyl oxidase transcriptional regulatory sequences will
be defined to investigate how the gene is switched off during ras
transformation, and how reversion with interferon leads to the
restoration of expression. Since demethylation of revertants
caused retransformation and loss of lysyl oxidase expression, the
control region may require methylation for activity. Positive
and/or negative regulatory proteins that bind to the
transcriptional regulatory control sequences, perhaps induced by
either interferon or ras, will be identified and studied. The
possible coordinate regulation of lysyl oxidase, collagen
structural genes, and enzymes involved in collagen synthesis
following ras transformation and reversion will be investigated.
Lysyl oxidase expression in cell lines transformed by oncogenes
other than ras will also be studied to reveal any similarities in
method of action or interrelationships among ras and other
oncogenes. If a relationship exists between lysyl oxidase activity
and normal cell growth and behavior, understanding the regulatory
mechanisms of this gene may provide opportunities for therapy:
drugs that modify lysyl oxidase expression can be identified, and
possibly in the future, gene replacement therapy could be
considered. Cell lines of human cancers that arise from cells that
produce collagen or elastin and lysyl oxidase will be examined for
alterations in lysyl oxidase message expression and enzyme activity
as well as collagen or elastin levels. If lysyl oxidase gene
expression is decreased in any of these human cancers, expression
experiments employing the human lysyl oxidase gene will be
performed to attempt reversion. Lysyl oxidase has also been
localized to some types of epithelia cells. Tumors arising from
these tissues will be examined for any changes in lysyl oxidase
expression. Normal tissue and cell lines derived from tumors of
tissues that show a high incidence of mutation in the ras oncogene
will also be examined to determine if there is a correlation
between lysyl oxidase expression and transformation similar to that
seen in the mouse fibroblast system. The relationship between
immature collagen and elastin in cell matrix and possible changes
in the binding/activity of growth-promoting or -controlling factors
will also be studied.
赖氨酰氧化酶的功能是作为一种抑制剂,
ras癌基因的表型表达。 NIH 3 T3小鼠细胞
LTR-c-H-ras转化表达非常低水平的赖氨酰
氧化酶;表达恢复后,干扰素β介导
逆转 回复突变体被赖氨酰氧化酶再转化
反义表达构建体;将原始转化细胞
用赖氨酰氧化酶正义表达转染后回复
构建体 赖氨酰氧化酶转录调控序列将
被定义为研究在ras过程中基因是如何被关闭的。
转化,以及干扰素逆转如何导致
恢复表达。 由于回复突变体的去甲基化
引起再转化和赖氨酰氧化酶表达的丧失,
控制区可能需要甲基化才能具有活性。 积极
和/或负调节蛋白,其结合到
转录调控序列,可能是由
干扰素或ras将被鉴定和研究。 的
赖氨酰氧化酶、胶原蛋白
结构基因和参与胶原蛋白合成的酶
随后将研究Ras转化和逆转。
赖氨酰氧化酶在癌基因转化细胞系中的表达
除了RAS之外,还将研究以揭示
行动方法或RAS与其他
致癌基因 如果赖氨酰氧化酶的活性
和正常的细胞生长和行为,了解调节
该基因的机制可能为治疗提供机会:
可以鉴定修饰赖氨酰氧化酶表达的药物,
在未来,基因替代疗法可能
考虑了 人类癌症的细胞系,
产生胶原蛋白或弹性蛋白和赖氨酰氧化酶将被检查
赖氨酰氧化酶信息表达和酶活性的改变
以及胶原蛋白或弹性蛋白水平。 如果赖氨酰氧化酶基因
在任何这些人类癌症中表达降低,
使用人赖氨酰氧化酶基因的实验将是
尝试恢复。 赖氨酰氧化酶也被
局限于某些类型的上皮细胞。 肿瘤来源于
将检查这些组织中赖氨酰氧化酶的任何变化
表情 来源于肿瘤的正常组织和细胞系
ras癌基因突变发生率高的组织
也将进行检查,以确定是否存在相关性
赖氨酰氧化酶的表达和类似于
在小鼠成纤维细胞系统中可见。 的关系
细胞基质中未成熟胶原和弹性蛋白及其可能的变化
在生长促进或控制因子的结合/活性中
也将被研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT M FRIEDMAN其他文献
ROBERT M FRIEDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT M FRIEDMAN', 18)}}的其他基金
INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
- 批准号:
3175183 - 财政年份:1984
- 资助金额:
$ 14.4万 - 项目类别:
INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
- 批准号:
3175179 - 财政年份:1984
- 资助金额:
$ 14.4万 - 项目类别:
INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
- 批准号:
6632930 - 财政年份:1984
- 资助金额:
$ 14.4万 - 项目类别:
INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
- 批准号:
6024372 - 财政年份:1984
- 资助金额:
$ 14.4万 - 项目类别:
INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
干扰素对人类癌基因表达的抑制
- 批准号:
6045146 - 财政年份:1984
- 资助金额:
$ 14.4万 - 项目类别:
相似海外基金
Dopaminergic regulation by D-aminoacid oxidase, an enzyme implicated in schizophrenia
D-氨基酸氧化酶(一种与精神分裂症有关的酶)对多巴胺能的调节
- 批准号:
G0801352/1 - 财政年份:2009
- 资助金额:
$ 14.4万 - 项目类别:
Research Grant
L-Aminoacid oxidase, biochemical mechanisms and apoptose induction
L-氨基酸氧化酶、生化机制和细胞凋亡诱导
- 批准号:
5368381 - 财政年份:2002
- 资助金额:
$ 14.4万 - 项目类别:
Research Grants














{{item.name}}会员




